4 ms·
So YC Bio doesn't imply a much bigger investment for 20% equity anymore? Most bio startups will require a significant amount of capital to bootstrap. It's chea
by nextos 7y ago
So YC Bio doesn't imply a much bigger investment for 20% equity anymore?
Most bio startups will require a significant amount of capital to bootstrap. It's cheaper now, but still an order of magnitude more than for IT.
- nemanja-mit 7y agoSurprisingly, bio is pretty similar to software capital-wise, at least initially and the standard YC deal works well. Jared and Jorge wrote good pieces around this recently - https://blog.ycombinator.com/how-biotech-startup-funding-will-change-in-the-next-10-years/ https://blog.ycombinator.com/how-biotech-startup-funding-wil... https://techcrunch.com/2019/08/09/biotech-researchers-venture-into-the-wild-to-start-their-own-business/ https://techcrunch.com/2019/08/09/biotech-researchers-ventur... Case in point - Asher Bio from the most recent YC batch went from zero to a working molecule & in-vivo data in ~3 months on the standard deal - https://techcrunch.com/2019/08/20/here-are-the-82-startups-that-launched-on-day-2-of-ycs-s19-demo-days/ https://techcrunch.com/2019/08/20/here-are-the-82-startups-t...
- kayhi 7y agoI would see this more of a reflection of spend matching the access to capital not that bio is similar to software. The difference between moving atoms and bits is significant.